Is Elanco Animal Health (ELAN) Still A Bargain After 108% Gains?
Elanco Animal Health stock has delivered a 107.8% return over the past three years, yet the current valuation checks and intrinsic value work suggest the shares may still be trading below what the business could be worth on fundamentals.
- Over the past three years, Elanco Animal Health has returned 107.8%, which puts recent price action front and center for anyone weighing up what is already reflected in the share price.
- For valuation, the key upside driver is how effectively Elanco Animal Health can convert its revenue into steady, cash based returns, while the main risk is that any setback in profitability or cash generation would make the current price look less of a bargain.
- On Simply Wall St's broader checks, Elanco Animal Health screens as undervalued in 6 of 6 valuation tests, which points to a stock that still leans cheap across several methods rather than just one.
The stock's next move may depend on whether that apparent undervaluation, including the Discounted Cash Flow (DCF) estimate that currently implies a 34.8% discount to intrinsic value, proves to be a genuine margin of safety or a sign the market is still cautious for good reason.
Is Elanco Animal Health Still Cheap on Cash Flow?
The Discounted Cash Flow (DCF) model estimates what Elanco Animal Health could be worth based on its projected cash generation. On the latest twelve month figures, the company produced about $355.3 million of free cash flow, and the model assumes those cash flows continue growing rather than shrinking over time.
Feeding those projections into a 2 Stage Free Cash Flow to Equity framework produces an estimated intrinsic value of about $38 per share. Compared with the current share price, the DCF implies the stock trades at a 34.8% discount. This indicates that Elanco Animal Health may be priced below what its cash flows suggest it could be worth if the projections are met.
On this cash flow view, Elanco Animal Health stock appears undervalued relative to the DCF estimate of intrinsic value.
Our Discounted Cash Flow (DCF) analysis suggests Elanco Animal Health is undervalued by 34.8%. Track this in your watchlist or portfolio, or discover 49 more high quality undervalued stocks.
Is Elanco Animal Health a Bargain on Sales?
A P/S multiple is a useful way to look at Elanco Animal Health because revenue tends to be more stable than earnings for many pharmaceutical companies. Elanco Animal Health currently trades on a P/S of about 2.5x, which is below the Pharmaceuticals industry average of around 4.9x and also below the peer group average of about 4.9x. That alone points to the market valuing each dollar of Elanco Animal Health's sales at a lower level than many comparable stocks.
Simply Wall St's fair P/S ratio for Elanco Animal Health, which blends factors such as margins, size and risk profile, sits higher at roughly 4.6x. Compared with that benchmark, the current 2.5x multiple implies the stock would need a sizable rerating just to line up with what those fundamentals suggest could be a more typical sales based valuation.
On this P/S measure, Elanco Animal Health stock appears undervalued compared with both its tailored fair multiple and the broader industry.
See what the numbers say about this price — find out in our valuation breakdown.
The Elanco Animal Health Narrative: What Would Justify Today's Price?
Simply Wall St Narratives for Elanco Animal Health pick up where the valuation work leaves off by spelling out which paths for Elanco Animal Health's growth, margins and earnings would need to hold for the stock to be worth meaningfully more or less than today's price, and they sit on the company's Community page. Each Narrative sets out a fair value as a thesis about how the business could develop over time, so you can see how that view holds up as new information arrives.
One of the top community narratives on Elanco Animal Health: 7% undervalued
"Elevated R&D spending, regulatory pressures, and competition from generics will limit profitability and strain Elanco's margin growth..."
Read one of the top narratives on Elanco Animal Health
Do you think there's more to the story for Elanco Animal Health? Head over to our Community to see what others are saying!
The Bottom Line
For Elanco Animal Health, both the Discounted Cash Flow (DCF) intrinsic value work and the sales based multiples are pointing in the same direction, with the stock screening as undervalued across the broader checks. That alignment suggests the current price is still not fully reflecting the cash flow profile and revenue base implied by those models. From here, the key question for you is whether Elanco Animal Health can sustain and convert its business into reliable cash generation, because that is what ultimately needs to hold for the apparent discount to be an opportunity rather than a value trap.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com